Gland Pharma invests USD 21 million as Jefferies rates Gland Pharma stock Buy

Published on 10/14/2026 at 06:22 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The board approved 60.00 percent of Novelstar on October 1, 2026. Jefferies set a Buy target of INR 3,350.00 for Gland Pharma stock.

US expansion and valuation

On October 1, 2026, the board approved a USD 21 million US investment.
Gland Pharma USA will acquire 60.00 percent of Novelstar Pharma.
Jefferies rates the stock Buy with an INR 3,350.00 target.

Gland Pharma, INE068V01023, Illustration mit AI erstellt.

Gland Pharma approved a USD 21 million US expansion on October 1, 2026, while CNBC TV18 reported that Jefferies rates Gland Pharma stock Buy and assigns an INR 3,350.00 target. The combination gives the announcement an operating angle and a valuation reference.

US expansion gets a defined structure

The board approved the investment in Gland Pharma USA, which will subscribe to 60.00 percent of newly incorporated Novelstar Pharma. The transaction is intended to expand Gland Pharma's business in the United States and is scheduled for completion by October 31, 2026, according to Gland Pharma.

Novelstar will become a subsidiary of Gland Pharma USA and a step-down subsidiary of Gland Pharma. Its post-acquisition share capital is set at USD 35.00 million, giving the deal a measurable structure beyond the headline investment.

What do the latest figures show?

Gland Pharma's first quarter of fiscal 2027 revenue reached INR 18.00 billion, while net income stood at INR 3.17 billion, according to Simply Wall St. Net margin rose to 17.60 percent from 14.30 percent in the comparable period, a quantified improvement that supports the expansion narrative while leaving execution as the key test.

Three dated developments

On August 10, 2026, Gland Pharma reported first-quarter fiscal 2027 revenue of INR 18.00 billion, according to Fyers. On September 4, 2026, Fosun Pharma sold a 6.00 percent Gland Pharma stake in a block deal worth INR 28.00 billion, The Economic Times reported. On October 1, 2026, the company approved the USD 21 million investment and the 60.00 percent Novelstar stake.

Dates investors can track

The proposed Novelstar transaction is due by October 31, 2026, while shareholder e-voting on Xingli Wang's appointment runs through November 5, 2026, according to Scanx. These dates place the US expansion and board change on separate but connected corporate timelines.

Market value on October 14

Gland Pharma's market capitalization was INR 506.1 billion on October 14, 2026. The company operates in healthcare and specializes in injectable pharmaceutical formulations for India, the United States, Europe, Canada, Australia and New Zealand.